<DOC>
	<DOCNO>NCT02892422</DOCNO>
	<brief_summary>To evaluate safety tolerability long-term treatment Lu AF35700 .</brief_summary>
	<brief_title>Flexible-dose , Long-term Safety Study Lu AF35700 Adult Patients With Schizophrenia</brief_title>
	<detailed_description>Safety study patient schizophrenia participate complete study investigate Lu AF35700 include Studies 16159A 16323A . Or patient schizophrenia switch antipsychotic treatment potentially beneficial accord investigator 's clinical judgement .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>For 16159Apatients The patient complete Study 16159A . The patient able read understand Informed Consent Form . The patient sign Informed Consent Form specific Study 16159B . The patient potentially benefit 52week treatment Lu AF35700 accord investigator 's clinical judgement . For 16323Apatients The patient complete dosing period Study 16323A . The patient able read understand Informed Consent Form . The patient sign Informed Consent Form specific Study 16159B . The patient confirm diagnosis schizophrenia accord DSM5™ . The patient potentially benefit 52week treatment Lu AF35700 accord investigator 's clinical judgement . For Other Patients The patient schizophrenia , diagnose accord DSM5™ . The patient man woman , age ≥18 year . The patient prescribe oral antipsychotic treatment recommend dose range state summary product characteristic equivalent label 6 week prior Screening Visit . The patient PANSS total score ≥60 ≤90 Screening Baseline Visits . The patient Clinical Global Impression Severity Illness ( CGIS ) score ≤4 . The patient need change current antipsychotic treatment , accord investigator 's clinical judgement , patient potentially benefit switch another treatment include , limited , follow reason : lack adequate response current antipsychotic medication ; poor tolerability current antipsychotic medication ; unwillingness patient adhere current antipsychotic medication . For 16159Apatients The patient diagnose primary psychiatric disorder schizophrenia Study 16159A . The patient , opinion investigator , significant risk suicide , : Answers `` Yes '' question Suicidal Behaviour section ColumbiaSuicide Severity Rating Scale ( CSSRS ) , OR Answers `` Yes '' question 4 5 Suicidal Ideation section CSSRS For 16323Apatients The patient diagnose primary psychiatric disorder schizophrenia Study 16323A . The patient , opinion investigator , significant risk suicide , : Answers `` Yes '' question Suicidal Behaviour section CSSRS , OR Answers `` Yes '' question 4 5 Suicidal Ideation section CSSRS For Other Patients The patient current psychiatric disorder ( DSM5™ criterion ) schizophrenia establish primary diagnosis . The patient experience acute exacerbation psychotic symptom Screening Visit , Screening Baseline Visits Baseline Visit . The patient treat clozapine time Screening Visit . The patient substance use disorder ( except nicotine ) accord investigator 's judgment may compromise patient 's ability comply study procedure , preclude benefit study medication . The patient , opinion investigator , significant risk suicide , : Answers `` Yes '' question Suicidal Behaviour section CSSRS , OR Answers `` Yes '' question 4 5 Suicidal Ideation section CSSRS Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>